ANNEE 2021

Publié le 18/10/2022 à 10h29 (mis à jour le 25/10/2022 à 11h10)

PHARMACOLOGIE FONDAMENTALE

Gallais F, Ysebaert L, Despas F, De Barros S, Obéric L, Allal B, Chatelut E, White-Koning M.Population PK-PD Modeling of Circulating Lymphocyte Dynamics in Chronic Lymphocytic Leukemia Patients Under Ibrutinib Treatment. Clin Pharmacol Ther. 2021 Jul ;110(1):220-228.

Kermorgant M, Ben Salem J, Iacovoni JS, Calise D, Dahan L, Guiard B, Lopez S, Lairez O, Lasbories A, Nasr N, Pavy Le-Traon A, Beaudry F, Senard JM, Arvanitis DN. Cardiac sensory afferents modulate susceptibility to anxio-depressive behaviour in a mouse model of chronic heart failure.Front Physiol. 2021 Jul 14 ;12:692361.

PHARMACOLOGIE CLINIQUE

Besse-Pinot E, Pereira B, Durif F, Fantini ML, Durand E, Debilly B, Derost P, Moreau C, Hainque E, Rouaud T, Eusebio A, Benatru I, Drapier S, Guehl D, Rascol O, Maltête D, Lagha-Boukbiza O, Giordana C, Tir M, Thobois S, Hopes L, Hubsch C, Jarraya B, Rolland AS, Corvol JC, Devos D, Marques A ; Predistim Study Group. Preoperative REM Sleep Behavior Disorder and Subthalamic Nucleus Deep Brain Stimulation Outcome in Parkinson Disease 1 Year After Surgery.Neurology. 2021 Nov 16 ;97(20):e1994-e2006.

Boucherie DM, Duarte GS, Machado T, Faustino PR, Sampaio C, Rascol O, Ferreira JJ. Parkinson’s Disease Drug Development Since 1999 : A Story of Repurposing and Relative Success. J Parkinsons Dis. 2021 ;11:421-429.

Bouhanick B, Delchier MC, Lagarde S, Boulestreau R, Conil C, Gosse P, Rousseau H, Lepage B, Olivier P, Papadopoulos P, Trillaud H, Cremer A ; ADERADHTA group*. Radiofrequency ablation for adenoma in patients with primary aldosteronism and hypertension : ADERADHTA, a pilot study. J Hypertens. 2021 ;39:759-765.

Boussac M, Arbus C, Dupouy J, Harroch E, Rousseau V, Croiset A, Ory-Magne F, Rascol O, Moreau C, Rolland AS, Maltête D, Rouaud T, Meyer M, Drapier S, Giordana B, Anheim M, Hainque E, Jarraya B, Benatru I, Auzou N, Belamri L, Tir M, Marques AR, Thobois S, Eusebio A, Corvol JC, Devos D, Brefel-Courbon C ; PREDI-STIM study group. Personality dimensions of patients can change during the course of parkinson’s disease. PLoS One. 2021 ;16:e0245142.

Bureau C, Thabut D, Jezequel C, Archambeaud I, D’Alteroche L, Dharancy S, Borentain P, Oberti F, Plessier A, De Ledinghen V, Ganne-Carrié N, Carbonell N, Rousseau V, Sommet A, Péron JM, Vinel JP. The Use of Rifaximin in the Prevention of Overt Hepatic Encephalopathy After Transjugular Intrahepatic Portosystemic Shunt : A Randomized Controlled Trial.

Chevreau C, Massard C, Flechon A, Delva R, Gravis G, Lotz JP, Bay JO, Gross-Goupil M, Fizazi K, Mourey L, Paci A, Guitton J, Thomas F, Lelièvre B, Ciccolini J, Moeung S, Gallois Y, Olivier P, Culine S, Filleron T, Chatelut E. Multicentric phase II trial of TI-CE high-dose chemotherapy with therapeutic drug monitoring of carboplatin in patients with relapsed advanced germ cell tumors.

Del Campo N, Phillips O, Ory-Magne F, Brefel-Courbon C, Galitzky M, Thalamas C, Narr KL, Joshi S, Singh MK, Péran P, Pavy-LeTraon A, Rascol O. Broad white matter impairment in multiple system atrophy.

Delavoipière E, Fourage C, Macro M, Olivier-Abbal P, Fleck C, Mouchel C, Gavard M, Petitpain N, Muller C, Franceschi MP, Savary C, Fournel F, Chaillot F, Alix A, Peyro-Saint-Paul L, pour le groupe REVISE. Déclaration des erreurs médicamenteuses dans la recherches portant sue le medicament : place du pharmacien des essais cliniques ?

Dreyfus I, Maza A, Rodriguez L, Merlos M, Texier H, Rousseau V, Sommet A, Mazereeuw-Hautier J. Botulinum toxin injections as an effective treatment for patients with intertriginous Hailey-Hailey or Darier disease : an open-label 6-month pilot interventional study.

Faggianelli F Jr, Loundou A, Baumstarck K, Nathalie S, Auquier P, Eusebio A, Defebvre L, Brefel-Courbon C, Houeto JL, Maltete D, Tranchant C, Derkinderen P, Geny C, Krystkowiak P, Jean-Philippe B, Macia F, Durif F, Poujois A, Borg M, Azulay JP, Witjas T NS-Park FCRIN Network. Validation of a non-motor fluctuations questionnaire in Parkinson’s disease.

Fernández-Rodríguez B, Dupouy J, Harroch E, Fabre-Delcros MH, Barthélémy C, Loubière P, Barange K, Brefel-Courbon C, Rascol O, Ory-Magne F. Body mass index variations in patients with Parkinson’s disease treated with levodopa-carbidopa intestinal gel infusion : A case control study versus standard of care and subthalamic nucleus deep brain stimulation.

Fontaine L, Sibon I, Raposo N, Albucher JF, Mazighi M, Rousseau V, Darcourt J, Thalamas C, Drif A, Sommet A, Viguier A, Guenogo A, Januel A-C, Calvière L, Menegon P, Bonneville F, Tourdias T, W. Albers G, Cognard C, Olivot J-M, on behalf of the FRAME investigators. ASCOD Phenotyping of stroke with anterior large vessel occlusion treated by mechanical thrombectomy.

Frison E, Proust-Lima C, Mangin, JF, Habert MO, Bombois S, Ousset, PJ & al. Diabetes Mellitus and Cognition : Pathway Analysis in the MEMENTO.

Gaudineau A, Senat MV, Ehlinger V, Gallini A, Morin M, Olivier P, Roth E, Orusco E,, Javoise S, Fort J, Lvergne C, Arnaud C, Rozenberg P, Vayssiere C . Induction of labor at term with vaginal misoprostol or a prostaglandin E2 pressary : a noninferiority randomized controlled trial.

Hauser RA, Hattori N, Fernandez H, Isaacson SH, Mochizuki H, Rascol O & al. Efficacy of Istradefylline, an Adenosine A2A Receptor Antagonist, as Adjunctive Therapy to Levodopa in Parkinson’s Disease : A Pooled Analysis of 8 Phase 2b/3 Trials.

He L, Morley JE, Aggarwal G, Nguyen AD, Vellas B, de Souto Barreto P. Plasma neurofilament light chain is associated with cognitive decline in non-dementia older adults.

Jackson, H, Anzures-Cabrera, J, Taylor, KI, Pagano G. Hoehn and Yahr Stage and Striatal Dat-SPECT Uptake Are Predictors of Parkinson’s Disease Motor Progression.

Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P. Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease : the role of opicapone.

Katzenschlager R, Poewe W, Rascol O, Trenkwalder C, Deuschl G, Chaudhuri KR, Henriksen T, van Laar T, Lockhart D, Staines H, Lees A. Long-term safety and efficacy of apomorphine infusion in Parkinson’s disease patients with persistent motor fluctuations : Results of the open-label phase of the TOLEDO study.

Kermorgant M, Sadegh A, Geeraerts T, Varenne F, Liberto J, Roubelat FP, Bataille N, Bareille MP, Beck A, Godard B, Golemis A, Nasr N, Arvanitis DN, Hélissen O, Senard JM, Pavy-Le Traon A, Soler V. Effects of Venoconstrictive Thigh Cuffs on Dry Immersion-Induced Ophthalmological Changes.

Magnin A, Iversen VC, Calvo G, Čečetková B, Dale O, Demlová R, Blaskó G, Keane F, Kovacs GL, Levy-Marchal C, Monteiro EC, Palmisano L, Pella D, Portolés A, Rascol O, Schmid C, Tay F, von der Leyen H, Ohmann C. European survey on national harmonization in clinical research.

Marques A, Brefel-Courbon C. Chronic pain in Parkinson’s disease : Clinical and pathophysiological aspects.

Meyer M, Lamare F, Asselineau J, Foubert-Samier A, Mazère J, Zanotti-Fregonara P, Rizzo G, Delamarre A, Spampinato U, Rascol O, Pavy-Le Traon A, Tison F, Fernandez P, Sibon I, Meissner WG. Brain 5-HT1A receptor binding in multiple system atrophy : An [18 F]-MPPF PET Study.

Montastruc J-L, Biron P, Sommet A. Efficacy of COVID-19 vaccines : Several modes of expression should be presented in scientific publications .

Montfort A, Filleron T, Virazels M, Dufau C, Milhès J, Pagès C, Olivier P, Ayyoub M, Mounier M, Lusque A, Brayer S, Delord JP, Andrieu-Abadie N, Levade T, Colacios C, Ségui B, Meyer N. Combining Nivolumab and Ipilimumab with Infliximab or Certolizumab in Patients with Advanced Melanoma : First results of a Phase Ib clinical trial.

Mourey L, Le Louedec F, Ravaud A, Paludetto MN, Digue L, Gomez-Roca CA, Valentin T, Balardy L, Olivier P, Cabarrou B, Filleron T, Chatelut E. VOTRAGE study : Phase I dose-escalation study of pazopanib in unfit older patients.

Olivot JM, Albucher JF, Guenego A, Thalamas C, Mlynash M, Rousseau V, Drif A, Christensen S, Sommet A, Viguier A, Darcourt J, Calvière L, Menegon P, Raposo N, Januel AC, Bonneville F, Tourdias T, Mazighi M, Sibon I, Albers GW, Cognard C ; FRAME Investigators*. Mismatch Profile Influences Outcome After Mechanical Thrombectomy.

Pagano, G ; Boess, FG ; Taylor, KI ; Ricci, B ; Mollenhauer, B ; Poewe, W & al ; A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson’s Disease (PASADENA) : Rationale, Design, and Baseline Data.

Pan, H ; Peto, R ; Henao-Restrepo, AM ; Preziosi, MP ; Sathiyamoorthy, V ; Abdool Karim, Q & al. Repurposed Antiviral Drugs for Covid-19 - Interim WHO Solidarity Trial Results

Péran, P ; Salabert, AS ; Dondaine, T ; Leclerc, X ; Gros-Dagnac, H ; Ranjeva, JP & al. Functional connectivity and cognitive changes after donepezil treatment in healthy participants.

Petitpain N, Olivier P, Crépin S, Leone E, Ouk T, Villeneuve C, Muller C, Ruault S, Jamet A, Franceschi MP, Duranton S, Gavard M.  Overview of clinical trials vigilance units in French institutional sponsors. A study from the REVISE working group.

Poewe, W ; Volc, D ; Seppi, K ; Medori, R ; Lührs, P ; Kutzelnigg, A & al. Safety and Tolerability of Active Immunotherapy Targeting α-Synuclein with PD03A in Patients with Early Parkinson’s Disease : A Randomized, Placebo-Controlled, Phase 1 Study.

Raffin, J ; Rolland, Y ; Aggarwal, G ; Nguyen, AD ; Morley, JE ; Li, Y & al. Associations Between Physical Activity, Blood-Based Biomarkers of Neurodegeneration, and Cognition in Healthy Older Adults : The MAPT Study.

Rascol O, Cochen de Cock V, Pavy-Le Traon A, Foubert-Samier A, Thalamas C, Sommet A, Rousseau V, Perez-Lloret S, Fabbri M, Azulay JP, Corvol JC, Couratier P, Damier P, Defebvre L, Durif F, Geny C, Houeto JL, Remy P, Tranchant C, Verin M, Tison F, Meissner WG ; MSA-FLUO Study Group. Fluoxetine for the Symptomatic Treatment of Multiple System Atrophy : The MSA-FLUO Trial.

Rascol O, Negre-Pages L, Damier P, Delval A, Derkinderen P, Destée A, Fabbri M, Meissner WG, Rachdi A, Tison F, Perez-Lloret S ; COPARK Study Group. Correction to : Excessive buccal saliva in patients with Parkinson’s disease of the French COPARK cohort.

Rocha JF, Ebersbach G , Lees A , Tolosa E , Ferreira JJ , Poewe W & al. The Added Benefit of Opicapone When Used Early in Parkinson’s Disease Patients With Levodopa-Induced Motor Fluctuations : A Post-hoc Analysis of BIPARK-I and -II.

Roullet P, Vaiva G, Véry E, Bourcier A, Yrondi A, Dupuch L & al. Traumatic memory reactivation with or without propranolol for PTSD and comorbid MD symptoms : a randomised clinical trial.

Santin MDN, Voulleminot P, Vrillon A, Hainque E, Béreau M, Lagha-Boukbiza O, Wirth T, Montaut S, Bardinet E, Kyheng M, Rolland AS, Voirin J, Drapier S, Durif F, Eusebio A, Giordana C, Auzou N, Houeto JL, Hubsch C, Jarraya B, Laurencin C, Maltete D, Meyer M, Rascol O, Rouaud T, Tir M, Moreau C, Corvol JC, Proust F, Grabli D, Devos D, Tranchant C, Anheim M ; Predistim Study Group. Impact of subthalamic deep brain stimulation on impulse control disorders in parkinson’s disease : A prospective study.

Seners P, Oppenheim C, Turc G, Albucher JF, Guenego A, Raposo N, Christensen S, Calvière L, Viguier A, Darcourt J, Januel AC, Mlynash M, Sommet A, Thalamas C, Sibon I, Rousseau V, Tourdias T, Menegon P, Bonneville F, Mazighi M, Charron S, Legrand L, Cognard C, Albers GW, Baron JC, Olivot JM and on behalf of FRAME investigators. Perfusion Imaging and Clinical Outcome in acute Ischemic stroke with large core.

Shadrin AA, Mucha S, Ellinghaus D, Makarious MB, Blauwendraat C, Sreelatha AAK, Heras-Garvin A, Ding J, Hammer M, Foubert-Samier A, Meissner WG, Rascol O, Pavy-Le Traon A, Frei O, O’Connell KS, Bahrami S, Schreiber S, Lieb W, Müller-Nurasyid M, Schminke U, Homuth G, Schmidt CO, Nöthen MM, Hoffmann P, Gieger C, Wenning G. European Multiple System Atrophy Study Group, Gibbs JR, Franke A, Hardy J, Stefanova N, Gasser T, Singleton A, Houlden H, Scholz SW, Andreassen OA, Sharma M.  Shared genetics of multiple system atrophy and inflammatory bowel disease.

Tolosa E , Ebersbach G , Ferreira JJ , Rascol O , Antonini A , Foltynie T & al. The Parkinson’s Real-World Impact Assessment (PRISM) Study : A European Survey of the Burden of Parkinson’s Disease in Patients and their Carers.

PHARMACOVIGILANCE

Araujo M, Vabre C, Benevent J, Sommet A, Damase-Michel C, Hurault-Delarue C, Lacroix I. Risk of Pregnancy Termination and Congenital Anomalies After Domperidone Exposure : A Study in the EFEMERIS Database.Drug Saf. 2021 ; 44:787-796.

Azam C, Durrieu G, Deuilhe E, Lafaurie M. Amlodipine and perindopril-induced hypertrichosis in a six-year-old girl : a case report*. Therapies. 2021 ;76:481-483

Badier L, Toledano A, Porel T, Dumond S, Jouglen J, Sailler L & al. IgA vasculitis in adult patient following vaccination by ChadOx1 nCoV-19. Autoimmun Rev. 2021 ;20(11):102951.

Belliere J, Mazieres J, Meyer N, Chebane L, Despas F. Renal Complications Related to Checkpoint Inhibitors : Diagnostic and Therapeutic Strategies. Diagnostics (Basel). 2021 Jun 30 ;11(7):1187.

Bouhanick B, Montastruc F,Tessier F, Brusq C, Bongard V, Senard JM, Montastruc JL, Herin . Hypertension and Covid-19 vaccines : are there any differences between the different vaccines ? A safety signal. Eur J Clin Pharmacol. 2021 ;77:1937-1938.

Braillon A , Bewley S, Blumsohn A, Naudet F, Montastruc JL, Lexchin JR. Antidepressants are not safe during pregnancy and in women of child-bearing age. Br J Clin Pharmacol. 2021 ; 88(5):2448.

Chouchana L, Preta LH, Tisseyre M, Terrier B, Treluyer JM, Montastruc F. Kidney disorders as serious adverse drug reactions of remdesivir in coronavirus disease 2019 : a retrospective case-noncase study.Kidney Int. 2021 ;99(5):1235-1236.

De Canecaude C, Gazagne C, Paraire M, Durrieu G. Tobramycine eye drops and ocular myasthenia gravis reactivation : A case report. Therapies. 2021 ;76:252-253.

De Canecaude C, Rousseau V, Sommet A, Montastruc JL. Tramadol-induced hypoglycemia : A pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;35:933-936

De Germay S, Lafaurie M, Dupuy M, de Germay B. Meningiomas after cyproterone acetate exposure : Case reports in twin sisters. Therapies. 2021 ;76:255-257.

De Germay S, Lapeyre-Mestre M, Montastruc JL, Montastruc F. Atropinic burden and anticholinergic drugs : Interest and application in clinical practice in the elderly. Poids atropinique et medicaments anticholinergiques : interêt et application en pratique Clinique chez la personne âgée. Therapies. 2021 ;76(6):665-673.

Defer G, Fedrizzi S, Chevanne D, Montastruc F, Briant AR, Parienti JJ, Peyro-Saint-Paul L ; French Vigip SEP Study Group ; Société Francophone de la Sclérose en Plaques (SFSEP). Adverse drug reaction reporting using a mobile device application by persons with multiple sclerosis : A cluster randomized controlled trial. Drug Saf. 2021 ;44:223-233.

Gainville A, Rousseau V, Kaguelidou F, Boyer Gervoise M, Michot J, Pizzoglio‑Bellaudaz V, Chebane L, Weckel A, Montastruc JL, Durrieu G. Drug‑induced hearing loss in children : An analysis of spontaneous reports in the french pharmacovigilance database. Pediatric Drugs. 2021 ;23:87-93.

Grandvuillemin A, Drici MD, Jonville‑Bera AP, Micallef J, Montastruc JL, the French Pharmacovigilance Network. French pharmacovigilance public system and COVID‑19 Pandemic. Drug Saf. 2021 ;44:405-408.

Gras-Champel V, Liabeuf S, Baud M, Albucher JF, Benkebil M, Boulay C,Bron A, Kaddissi AL,Gautier S, Geeraerts T,Girot M, Grandvuillemin A, Laujin H, Jonville-Béra AP, Masmoudi K, Massardier E, Micallef J, Mounier C, Montastruc F, Pariente A, Perez J, Raposo N, Salvo F, Valnet-Rabier MB, Vial T and the French Network. Atypical thrombosis associated with VaxZevria (AstraZeneca) vaccine : Data from the french network of regional Pharmacovigilance centres. Therapies. 2021 ;76:361-382.

Guion-Firmin J, Tessier S, Marion Lepelley, Faillie J-L, Montastruc J-L. Diarrhoea with the angiotensin receptor neprilysin inhibitorsacubitril + valsartan : A pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;1–12

Guion-Firmin J, Tessier S, Montastruc J-L. Diarrhoea and angiotensin II receptor blockers : Is there any difference between the different drugs ? Fundam Clin Pharmacol. 2021 ;1-5.

Hamard J, Rigal M, Gony M, Bagheri H. Lacosamide-induced personality changes : An unexpected adverse effect. Fundam Clin Pharmacol. 2021 ;36(1) :224-226.

Icard C, Mocquot P, Nogaro JC, Despas F, Gauthier M. Lenalidomide-induced arthritis : A case report and review of literature and pharmacovigilance databases. J Oncol Pharm Pract. 2022 Mar ;28(2):453-456.

Lacroix C, Bera-Jonville AP, Montastruc F, Velly L, Micallef J, Guilhaumou R. Serious Neurological Adverse Events of Ceftriaxone. Antibiotics. 2021 ;10:540.

Lacroix I, Hurault-Delarue C, Viard D, Revol B, Chaalel L, Damase-Michel C. Use of triptans during pregnancy ? With caution ! Therapies. 2021 ;76:477-478

Montastruc JL , Durrieu G. Amiodarone and Parkinsonism : a pharmacovigilance study. Fundam Clin Pharmacol. 2021 ;35:781-784.

Montastruc JL, Guion Firmin1 J, de Canecaude C, Ruyssens Witrand A, Durrieu G, Lafaurie M, Sommet A. Drugs and Dupuytren’s disease : a pharmacovigilance study in VigiBase®. European Journal of Clinical Pharmacology. 2021 ;77:1587–1588.

Montastruc JL, Lafaurie M, de Canecaude C, Durrieu G, Sommet A, Montastruc F, Bagheri H. Fatal adverse drug reactions : a worldwide perspective in the World health organisation pharmacovigilance database. Br J Clin Pharmacol. 2021 ;87:4334-4340.

Nguyen KD, Vu DH, Nguyen HA, Dao VT, Montastruc JL, Bagheri H. Risk comparison of beta-lactam-induced anaphylaxis : Therapeutic stratification analysis in a Vietnamese pharmacovigilance database. J Clin Pharm Ther. 2021:46:950-956 .

Quinta JB, Montastruc F, Sommet A, Touafchia A, Galinier M, Reber L, Rousseau V, Guilleminault L. Cardiovascular adverse effects of anti-IL5/IL5Rα therapies : a real-world study. J Allergy Clin Immunol Pract. 2021 ;9:1411-1413.

Rousset S, Lafaurie M, Guet-Revillet H, Protin C, Le Grusse J, Derumeaux H, Gandia P, Nourhashemi F, Sailler L, Sommet A, Delobel P, Martin-Blondel G. Safety of pyrazinamide for the treatment of tuberculosis in older patients over 75 years of age : A retrospective monocentric cohort study. Drugs Aging. 2021 ;38:43-52.

Saint-Lary L, Diallo A, De Monteynard LA, Paul C, Marchand L, Tubiana R, Warszawski J, Mandelbrot L, Rekacewicz C, Petrov-sanchez V, Faye A, Sibuide J, Dabis F, Sommet A, Leroy V. In utero ex posure to antiretroviral drugs and pregnancy outcomes : Analysis of the French ANRS parmacovigilance database. Br J Clin Pharmacol. 2021 ;1-23.

Scailteux LM, Lacroix C, Bergeron S, Despas F, Sassier M, Triquet L, Picard S, Oger E, Polard E ; et le réseau français des Centres régionaux de pharmacovigilance. Adverse drug reactions profiles for abiraterone and enzalutamide : A pharmacovigilance descriptive analysis. Therapies. 2021 ; 76:455-465.

Strumia M, Perrin ML, Patras de Compaigno E, Conte C, Montastruc F, Lapeyre-Mestre M, Sibaud V, Despas F. Dermatological adverse drug reactions of anticancer drugs : International data of pharmacovigilance : VigiBase®. Therapie. 2021 Dec 11:S0040-5957(21)00257-2.

Teboul A, Chouchana L, Durrieu G, Eftekhari P, Treluyer JM, Mouthon L, Chaigne B. Drug-induced eosinophilic fasciitis : A dual pharmacovigilance analysis. J Am Acad Dermatol. 2021 May 27:S0190-9622(21)01019-7.

Touafchia A, Bagheri H, Carrié D, Durrieu G, Sommet A, Chouchana L, Montastruc F. Serious bradycardia and remdesivir for coronavirus 2019 (COVID-19) : a new safety concerns. Clin Microbiol Infect. 2021 ;27:791.e5-791.e8.

Tournon N, Bertrand L, Bagheri H, Amar J. Severe hypertensive flare-up after intravitreal injection of ranibizumab for retinal venous branch occlusion. Fundam Clin Pharmacol. 2021 ;35:785-788.

Vasseur M, Tambon M, Gony M, Lebrun N, Bagheri H. Pneumopathie médicamanteuse ou liée à la COVID-19 : un train peu en cacher un autre ! Therapies. 2021 ;76:374-376

ADDICTOVIGILANCE

Bouquet E, Pain S, Eiden C, Jouanjus E, Richard N, Fauconneau B, Pérault-Pochat MC ; French Addictovigilance Network. Adverse events of recreational cannabis use reported to the French addictovigilance network (2012-2017). Br J Clin Pharmacol. 2021 Oct ;87(10):3925-3937.

Eiden C, Vincent M, Serrand C, Serre A, Richard N, Picot MC & al. Health consequences of cocaine use in France : data from the French Addictovigilance Network. Fundam Clin Pharmacol.2021 ;35 :455-465.

Jobert A, Laforgue EJ, Grall-Bronnec M, Rousselet M, Péré M, Jolliet P, FAN-Network (Jouanjous E), Feuillet F, Victorri-Vigneau C. Benzodiazepine withdrawal in older people : what is the prevalence, what are the signs, and which patients ? Eur J Clin Pharmacol. 2021 ;77:171-177.

Jouanjus E, Sans-Pola C, Mainoli B, Javid FA, Ekheden I, Working Group on Medical Cannabis Projets of the EACPT Young Clinical Parmacologists. Establishing and Evaluating a Study Questionnaire on Knowledge and Attitudes of Healthcare Professionals Towards Recreational and Medical Cannabis Across Europe. Clin Drug Investig. 2021 ;41(8) :701-710

Lapeyre-Mestre M.  Bacterial infections in people who inject psychoactive substances : An observational study in a French university hospital. A comment - Therapies. 2021 ;76(6) :525-526

Micallef J, Mallaret M, Lapeyre-Mestre M, Daveluy A, Victorri-Vigneau C, Peyrière H, Debruyne D, Deheul S, Bordet R, Chevallier C, Perault-Pochat MC, Le Boisselier R, Libert F, Chaouachi L, Gillet P. French Association of Addictovigilance Centres. Warning on increased serious health complications related to non-medical use of nitrous oxide. Therapies. 2021 ; 76 :478-479.

Soeiro T , Lacroix C , Pradel V , Lapeyre-Mestre M , Micallef J. Early Detection of Prescription Drug Abuse Using Doctor Shopping Monitoring From Claims Databases : Illustration From the Experience of the French Addictovigilance Network. Front Psychiatry. 2021 ;12 :640120.

Tambon M, Ponté C, Jouanjus E, Fouilhé N, Micallef J, Lapeyre-Mestre M ; French Addictovigilance Network (FAN). Gabapentinoid Abuse in France : Evidence on Health Consequences and New Points of Vigilance. Front Psychiatry. 2021 ;12:639780.

Victorri-Vigneau C , Laforgue EJ, Grall-Bronnec M, Guillou-Landreat M, Rousselet M, Guerlais M & al. Are Seniors Dependent on Benzodiazepines ? A National Clinical Survey of Substance Use Disorder. Clin Pharmacol Ther.2021 ;109(2) :528-535 .

PHARMACO - EPIDEMIOLOGIE

Abdeljalil AB, de Mauléon A, Baziard M, Vellas B, Lapeyre-Mestre M, Soto M Antidepressant Use and Progression of Mild to Moderate Alzheimer’s Disease : Results from the European ICTUS Cohort. JAMDA. 2021 ;22:433-439.

Araujo M, Hurault-Delarue C, Sommet A, Damase-Michel C, Benevent J, Lacroix I. Drug prescriptions in French pregnant women between 2015 and 2016 : A study in the EGB database. Therapies. 2021 ;76:239-247.

Bagheri H. Ambulatory drug changes in the elderly after hospital discharge : A cohort study. Therapies. 2021 ;76(6):523-524.

Blotière PO, Damase-Michel C, Weill A, Maura C. Dispensing of Potentially Harmful Prescription drugs in 1.8 million pregnant women in France : A nationwide study based on two risk classification systems.Dug Saf. 2021 ;44 :1323-1339.

Chu TH, Rueter M, Palmaro A, Lapeyre-Mestre M. Potential inappropriate use of strong opioid analgesics in cancer outpatients during the last year of life in France and associated factors. Br J Clin Pharmacol. 2021.

Daveluy A, Micallef J, Sanchez-Pena P, Miremont-Salamé G, Lassalle R, Lacueille C, Grelaud A, Corand V, Victorri-Vigneau C, Batisse A, Le Boisselier R, Peyrière H, Frauger E, Lapeyre-Mestre M, Haramburu F. Ten-year trend of opioid and nonopioid analgesic use in the French adult population. Br J Clin Pharmacol. 2021 ;87:555-564.

Fabbri M, Leung C, Baille G, Bereau M, Brefel-Courbon C, Castelnovo G,Carriere N, Damier P, Defebvre L, de Maindreville AD, Fluchere F, Fuzzatti M, Grabli D, Maltete D, Rousseau V, Sommet A, Thalamas C, Thiriez C, Rascol O, Ory-Magne F. A French survey on the lockdown consequences of COVID-19 pandemic in Parkinson’s disease. The ERCOPARK study. Parkinsonism and related disorders. 2021 ;89:128-133.

Garcia P, Montastruc JL, Rousseau V, Hamard J, Sommet A, Montastruc F. β-adrenoceptor antagonists and nightmares : A pharmacoepidemiological-pharmacodynamic study. J Psychopharmcol. 2021 ; Dec ;35(12):1441-1448.

Gault, N ; Esposito-Farèse, M ; Revest, M ; Inamo, J ; Cabié, A ; Polard, É & al. Chronic use of renin-angiotensin-aldosterone system blockers and mortality in COVID-19 : A multicenter prospective cohort and literature review. Fundam Clin Pharmacol. 2021 ;35(6) :1141-1158.

Gerardin M, Rousselet M, Couec ML, Masseau A, Guerlais M, Authier N, Deheul S, Roussin A, Micallef J, Djezzar S, French Addictovigilance Network (FAN) ; Feuillet F, Jolliet P, Victorri-Vigneau C. Descriptive analysis of sickle cell patients living in France : The PHEDRE cross-sectional study. PLoS One. 2021 ;16:e0248649.

Hall MD, Baruch J, Carson G, Citarella BW, Dagens A, Dankwa EA & al. Ten months of temporal variation in the clinical journey of hospitalised patients with COVID-19 : An observational cohort. Elife. 2021 ;Nov 23 ;10:e70970.

Herin F, Othenin J, Jouanjus E, Rousseau V, Niezborala M, Lapeyre-Mestre M. Evolution of medication consumption in a working environment in France : Results of the four waves of the "Drugs and Work" study (1986-2016). Pharmacoepidemiol Drug Saf. 2021 ;30:661-668.

Hurault-Delarue C, Araujo M, Vabre C, Benevent J, Damase-Michel C, Lacroix I. What changes in prescription patterns of antiemetic medications in pregnant women in France ? Fundam Clin Pharmacol. 2021 ;35:1159-1167.

Jouanjus E, Gibaja V, Fabre F, Lapeyre-Mestre M, OSIAP Working Group on opioid cough suppressants. Medical prescription forms of opioid cough suppressants falsified by the patients before and after they switched from over-the-counter to prescription-only in France. Br J Clin Pharmacol. 2021 ;1-9.

Lafaurie M, Maquet J, Baricault B, Ekstrand C, Christiansen CF, Linder M, Bahmanyar S, Nogaard M, Sailler L, Lapeyre-Mestre M, Sommet A, Moulis G. Risk factors of hospitalization for thrombosis in adults with primary immune thrombocytopenia, including disease-specific treatments : a French nationwide cohort study. British Journal of Heamatology. 2021 ;195:456-465.

Lafaurie M, Martin-Blondel G, Delobel P, Charpentier S, Sommet A, Moulis G. Outcome of patients hospitalized for COVID-19 and exposure to angiotensin-converting enzyme inhibitors and angiotensin-receptor blockers in France : results of the ACE-CoV study. Fundam Clin Pharmacol. 2021 ;35:194-203.

Lafaurie M, Martin-Blondel G, Delobel P, Kamar N, Charpentier S, Sommet A, Moulis G ; Covid-Clinic-Toul investigators. Impact of previous exposure to systemic corticosteroids on unfavorable outcome in patients hospitalized for COVID-19. BMC Pharmacol Toxicol. 2021 ;Mar11 ;22:14.

Lapeyre-Mestre M, Boyer A, Ponté C, Daveluy A, Godeau E. Consommation de substances chez les jeunes : du médicament aux substances illicites. Therapies. 2021 ;76:31-35.

Larcin L, Lona M, Karakaya G, Van Espen A, Damase-Michel C, Kirakoya- Samadoulougou F. Using administrative healthcare database records to study trends in prescribed medication dispensed during pregnancy in Belgium from 2003 to 2017. Pharmacoepidemiol Drug Saf 2021 ;30 :1224-1232

Maquet J, Lafaurie M, Sailler L, Lapeyre-Mestre M, Moulis G. Correspondence on risk of systemic lupus erythematosus after immune thrombocytopenia and autoimmune haemolytic anaemia : a nationwide French study. Ann Rheum Dis. 2021 ; Dec 11 : annrheumdis-2020-219470.

Maquet J, Lafaurie M, Walter O, Sailler L, Sommet A, Lapeyre-Mestre M, Michel M, Moulis G. Epidemiology of autoimmune hemolytic anemia : a nationwide population-based study in France. Am J Hematol. 2021 Aug 1 ;96(8):E291-E293.

Neumane S, Câmara-Costa H, Francillette L, Araujo M, Toure H, Brugel D, Laurent-Vannier A, Ewing-Cobbs L, Meyer P, Dellatolas G, Watier L, Chevignard M. Functional outcome after severe childhood traumatic brain injury : Results of the TGE prospective longitudinal study. Ann Phys Rehabil Med. 2021 ;64:101375.

Pajiep M, Conte C, Huguet F, Gauthier M, Despas F, Lapeyre-Mestre M. Patterns of Tyrosine Kinase Inhibitor Utilization in Newly Treated Patients With Chronic Myeloid Leukemia : An Exhaustive Population-Based Study in France. Front Oncol. 2021 ;30 ;11:675609.

Rahman A, Kane J, Montastruc F, Renoux C. Trends in new prescription of gabapentinoids and of coprescription with opioids in the four nations of the United Kingdom, 1993-2017. Br J Clin Pharmacol. 2021 ;87:3349-3353.

Revol B, Delorme J, Jouanjus E, Spadari M, Djezzar S, Lepelley M, Khouri C, Fouilhé Sam-laï N, Mallaret M, et le réseau français des centre d’addictovigilance. Trente ans d’abus de néfopam en France. Therapies. 2021 ;76:527-537.

Scailteux LM, Campillo-Gimenez B, Kerbrat S, Despas F, Mathieu R, Vincendeau S, Balusson F, Happe A, Nowak E, Oger E. Overall survival among chemotherapy-naïve castration-resistant prostate cancer patients under abiraterone versus enzalutamide : a direct comparison based on a 2014-2018 French population study (the SPEAR cohort). Am J Epidemiol. 2021 ;190:413-422.

Soeiro T, Pradel V, Lapeyre-Mestre M, Micallef J. Evolution of doctor shopping for oxycodone in the 67 million inhabitants in France as a proxy for potential misuse or abuse. Pain. 2021 ;162:770-777.

Tran VT , Mahévas M , Bani-Sadr F , Robineau O , Perpoint T , Perrodeau E & al. Corticosteroids in patients hospitalized for COVID-19 pneumonia who require oxygen : observational comparative study using routine care data. Clin Microbiol Infect.2021 ;27 :603-610.

Walter O, Maquet J, Derumeaux H, Moulis G, Lafaurie M. Validation of Discharge Diagnosis of Sickle Cell Disease Vaso-Occlusive Episodes in the French Hospital Electronic Database. Clin Epidemiol.2021 ;13 :717-720.

INFORMATIONS SUR LE MEDICAMENT

Carton L, Bordet R, Montastruc F, Guilhaumou R. Towards personalized pharmacology : Antipsychoticsand schizophrenia. Therapies. 2021 ;76:137-147.

Castanié M, Juillard-Condat B, Galian C, Giroud JP, Bagheri H. Analyse des modifications de statut règlementaire des médicaments en France. Therapies. 2021 ;76:31-47.

Cottin J, Benevent J, Khettar S, Lacroix I. COVID-19 vaccines and pregnancy : Wath do we know ? Thérapie 2021 ; 76:361-382.

Geeraerts T, Montastruc F, Bonneville F, Mémier V, Raposo N ; Toulouse Vitt Study Group. Oxford-AstraZeneca COVID-19 vaccine-induced cerebral venous thrombosis and thrombocytopaenia : A missed opportunity for a rapid return of experience. Anaesth Crit Care Pain Med. 2021 Aug ;40(4):100889.

Huguier M, Tillement JP, Montastruc JL, Olié JP, Lechat P, Bouvenot G, Milhaud G. Rapport 21-01. Le bon usage des médicaments. Bull Acad Natl Med. 2021 ;205:331-336.

Montastruc JL. 1921-2021, from insulin to new hypoglycaemic drugs : 100 years of pharmacological reseach in diabetes mellitus. Therapies. 2021 ;76:517-521.

Montastruc JL. Therapies celebrated its 75th anniversary ! Therapies.2021 ;76:1-4.

Montastruc JL, Lafaurie M, de Canecaude C, Montastruc F, Bagheri H, Durrieu G, Sommet A. COVID-19 vaccines : A perspective from social pharmacology. Therapies. 2021 ;76 :311-315.

Montastruc JL. Vitamine D et Covid-19 : qu’en est-il vraiment ? Rev Prescrire. 2021 ;41:74.

Montastruc JL. La France malade du médicament : 110 milliards d’euros plus tard, B. Bégaud.Ed. de l’obervatoire, Paris (2020). Therapies. 2021 ;76:516

Olanow CW, Poewe W, Rascol O, Stocchi F. On-Demand Therapy for OFF Episodes in Parkinson’s Disease. Mov Disord. 2021 ;36(10):2244-2253.

Rascol O, Fabbri M, Poewe W. Amantadine in the treatment of Parkinson’s disease and other movement disorders. Lancet Neurol. 2021 ;20(12):1048-1056.

Vaysse C, Fize AL, Despas F, Chantalat E, Serrano E, Beyne-Rauzy O, Rougé-Bugat ME. Small private online course in teaching oncology-feedback after 1 Year : What Lessons ? J Cancer Educ. 2021 ;36:65-71.